Objective Biotechnology Launches First-Ever Automated Microinjection Robot for Genetic Research

MINNEAPOLIS--(BUSINESS WIRE)--Objective Biotechnology, a pioneer in next-generation research tools, today announced the commercial launch of the Autoinjector, the first fully automated robotic system for microinjection in genetic research. Developed in collaboration with the University of Minnesota, the system was validated in a GENETICS study showing its speed, accuracy, and broad utility across model organisms.
Microinjection is an essential but slow step in genetic research, traditionally requiring technicians to manually align and inject each embryo with precision. The Autoinjector transforms this process by combining computer vision and machine learning, delivering consistent, high-precision injections up to four times faster than manual methods—while reducing training time from months to weeks.
The Autoinjector also enables entirely new high-throughput experiments that aren't feasible by hand. In the study published in GENETICS, researchers used it to inject over 20,000 uniquely barcoded DNA plasmids into 1,700 Drosophila embryos in just two days—generating more than 400 unique transgenic lines and, for the first time, allowing scientists to measure how many independent germline integrations occurred per embryo. The study also demonstrated that the Autoinjector significantly improved vitrification rates and post-thaw survival of zebrafish, outperforming traditional manual injection.
'The system has already demonstrated success in gene editing and transgenesis experiments across both insect and vertebrate models at multiple early-access sites,' said James Grabau, CEO of Objective Biotechnology. 'The Autoinjector is designed to remove a stubborn and persistent bottleneck in the process of generating transgenic models in a variety of species and applications.'
'The Autoinjector comes pre-loaded with injection protocols for commonly used model organisms such as Drosophila and zebrafish, and it can be fully customized for emerging or non-model species,' said Daryl Gohl, Chief Scientific Officer of Objective Biotechnology. 'This flexibility makes the Autoinjector particularly valuable for labs working across multiple species, providing them with the ability to streamline both basic and applied genetic research.'
Objective Biotechnology is a leader in developing innovative solutions for genetic engineering and neurotechnology. Its mission is to accelerate discovery by equipping scientists with cutting-edge tools that simplify, scale, and expand what's possible in modern genetics and neuroscience.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNN

11 hours ago

• CNN

Science recap: This week's discoveries include the fossilized skull of a mysterious, prehistoric human species

Tens of thousands of years ago, our species — Homo sapiens — mingled and interbred with other prehistoric humans: our distant cousins, the Neanderthals and Denisovans. Hundreds of Neanderthal fossils give us a good idea of their appearance, lives and relationships, but so little is known about Denisovans that they still don't have an official scientific name. Evidence of their existence has surfaced in faint traces, mapped by DNA markers that lurk in our own genetic makeup and confirmed by only a few fossil fragments. This week, however, a 146,000-year-old skull dredged out of a well in China in 2018 may just be a key missing piece to this cryptic evolutionary puzzle. A long time ago The nearly complete skull did not match any previously known species of prehistoric human. But two new studies — which researchers say are among the biggest paleoanthropology papers of the year — detail how scientists were able to extract genetic material from the fossil and help unravel this biological mystery. The DNA sample taken from 'Dragon Man,' as the specimen is called, revealed that he was in fact related to Denisovans, early humans who are thought to have lived between roughly 500,000 and 30,000 years ago. The finding could be monumental, helping to paint a fuller picture of a time when our own species coexisted with other prehistoric humans. Across the universe Astronomers have long grappled with the quandary of 'dark matter,' but plenty of enigmas surround regular matter as well. The proton-and-neutron-based atoms that we're familiar with are called baryonic matter. And this material is strewn between galaxies like intergalactic fog, making it extremely difficult to measure. Perhaps, that is, until now. A new study explains how scientists were able to observe the baryonic matter using the flashing of fast radio bursts. In a rare encounter, scientists have captured the first-ever footage of an elusive 3-foot-long squid alive in its deep-sea habitat. Unearthed Fruit, flowers, birds and musical instruments decorated the walls of a luxury villa — part of a site the excavation team dubbed the 'Beverly Hills' of Roman Britain — before the building was razed roughly 1,800 years ago. The frescoes were painstakingly pieced together by experts from the Museum of London Archaeology. Han Li, senior building material specialist at MOLA, described the effort as a 'once in a lifetime' opportunity. Romans invaded modern-day Britain in AD 43 and established Londinium, the precursor to modern London. The occupation lasted for almost 400 years. Curiosities Under the life-affirming glow of the sun, methane is a dangerous gas to be avoided. A heat-trapping chemical pollutant in Earth's atmosphere, methane exacerbates the climate crisis. But within the planet's deep recesses — thousands of feet below the ocean's surface off the US West Coast — the gas can be transformed into a nutritious meal. At least for spiders. Scientists say they've discovered three previously unknown species of sea spider living around methane seeps. In these marine habitats where sunlight can't reach, gas escapes through cracks in the seafloor and feeds bacteria that latch on to the spiders' exoskeletons. The bacteria convert carbon-rich methane and oxygen into sugars and fats the spiders can eat, according to a new study. The newfound Sericosura sea spiders may pass methane-fueled bacteria to their hatchlings as an easy source of food, the researchers suggest. Take note Check out these other must-read science stories from the week: — A SpaceX Starship rocket exploded during a routine ground test on Wednesday. Explore how this and other recent setbacks may affect the company's Mars ambitions. — A tiny brown moth in Australia migrates some 600 miles at night using the stars for navigation — something only humans and birds were known to do before. — A hunt for ghostly cosmic particles found anomalous signals coming from Antarctic ice. A new detector could help scientists explain what they are. — Researchers used DNA to reconstruct the face of a prehistoric woman who lived around 10,500 years ago in what's now Belgium, suggesting that skin color already varied considerably among different populations.

Business Wire

14 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Fox News

a day ago

• Fox News

Mysterious 'dragon man' skull found in the 1930s finally identified

A mysterious human skull found in the 1930s has been identified as an existing species after once being thought to be a new species all together, according to researchers. The studies — posted in the journals Cell and Science — have identified the 146,000-year-old skull known as "dragon man" has been categorized as a Denisovan. The researchers revealed that the Denisovans were discovered by their genomes and proteins to identify them. However, the reason it took so long to identify was that the attempts to extract DNA from a tooth failed. Researchers also tried extracting DNA from the Harbin cranium as well, which also failed. When those methods failed, researchers turned to using dental calculus, which uses calcified dental plaque. The calcified dental plaque could hold and protect DNA due to its dense crystalline structure that resists degradation in various environments. Researchers used bleach on the dental plaque in order to eliminate any possible modern-day DNA. Once extracted, researchers began to compare the genetic material discovered to previous samples. The researchers found that the "dragon man" was not a new species but was a Denisovan and the very first intact specimen to date. According to the researchers, Denisovans coexisted with modern-day humans and are closely related to Neanderthals. The "dragon man" was discovered in mysterious circumstances when a Chinese laborer working on a bridge over the Songhua River found it. The man kept the Harbin cranium well hidden as he was instructed to hide it from the Japanese army. The skull was donated shortly before his death in 2018, after which his family relocated the skull and gave it to the Geoscience Museum, Hebei GEO University professor Qiang Ji. While there are limitations to this study, the researchers said there is still so much to learn moving forward. It was called "dragon man" because it was found in the Heilongjiang province of China, which translates to Black Dragon River. Fox News Digital's Julia Musto contributed to this story.